<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112160</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012018-080</org_study_id>
    <nct_id>NCT04112160</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal</brief_title>
  <official_title>Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized double-blind controlled trial assessing the benefits of
      intramuscular ketorolac before or immediately after office ureteral stent removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are undergoing cystoscopy with ureteral stent removal at the University of Texas
      Southwestern Medical Center and have no contraindications to receiving ketorolac will be
      eligible. Patients will be randomized to receive either a 1 mL injection of ketorolac
      tromethamine or 1 mL injection of normal saline (0.9%) as the control arm. Ketorolac is a
      member of the pyrrolo-pyrrole group of non steroid anti inflammatory drugs. The mechanism of
      action of ketorolac, like that of other NSAIDs, is not completely understood but may be
      related to prostaglandin synthetase inhibition. The peak analgesic effect occurs within 2-3
      hours. If no contraindications exist, ketorolac can be safely given to patients of any age in
      the 30 mg intramuscular formulation if given as a one time dose according to the package
      insert.

      Normal saline contains 0.9% of Sodium chloride in each mL. Like ketorolac, it is a clear
      solution and given that there are no major side effects of normal saline it is a good control
      for our study. It is packaged in a single dose vial that contains 100 mL. It is preservative
      free and stored at room temperature (20-25Â°C). Local pain at the injection site may occur,
      temporarily.

      The investigators will specifically look at pain scores before and after stent removal as
      well as narcotic medication use, telephone calls and/or emergency room visits for pain. Based
      on the rate of renal colic from our quality improvement project and prior work, the
      investigators calculated the maximum number of local subjects to be consented for this study
      to be n=116 (see biostatistics section). The study is expected to last 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Unscheduled Return to Clinic or Emergency Room</measure>
    <time_frame>Seven days following ureteral stent removal.</time_frame>
    <description>Any unscheduled in-person clinical encounter secondary to renal colic following ureteral stent removal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Visual Analog Pain (VAS) Pain Scale Experienced by Participant 24 Hours Following Stent Removal</measure>
    <time_frame>Twenty-four hours following ureteral stent removal.</time_frame>
    <description>Perceived pain on a scale of 0-10 (0= no pain, 10= worst pain ever experienced) recorded by phone call 24 hours after stent removal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants That Experienced an Injection Complication</measure>
    <time_frame>Within thirty days post injection.</time_frame>
    <description>Determine if there is any infection site pain or reaction. Determine any complications related to administration of the medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Pain (VAS) Pain Scale 7 Days Following Stent Removal.</measure>
    <time_frame>Seven days following ureteral stent removal.</time_frame>
    <description>Perceived pain on a scale of 0-10 (0= no pain, 10= worst pain ever experienced) recorded by phone call 7 days after stent removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Required Opioid Medication Following Ureteral Stent Removal</measure>
    <time_frame>Twenty-four hours following stent removal.</time_frame>
    <description>Determine the use of opioid medications in morphine equivalents in the 24 hours following stent removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Days the Participant Missed Work</measure>
    <time_frame>Seven days following stent removal.</time_frame>
    <description>Determine amount of missed work or school due to renal colic following ureteral stent removal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Pain</condition>
  <condition>Urinary Stone</condition>
  <condition>Urinary Calculi</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 0.9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg of Ketorolac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>IM injection of either normal saline or Ketorolac</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>normal saline</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 18 to 79 who have undergone a cystoscopy with indwelling double-J ureteral
             stent placement at Clements University Hospital and are presenting to the office for
             cystoscopy and stent removal.

        Exclusion Criteria:

          -  eGFR &lt;50

          -  any active or history of peptic ulcer disease or GI bleeding

          -  Bleeding disorder, suspected of confirmed cerebrovascular bleeding, hemorrhagic
             diathesis, or incomplete hemostasis

          -  Concurrent use of Aspirin 325mg, wafarin, rivaroxaban, apixaban, clopidogrel, or
             heparin

          -  Allergic reaction to NSAIDs

          -  Concurrent use of other NSAIDs within 24 hours

          -  Pregnancy (ketorolac contraindicated in this population)

          -  Recent myocardial infarction (MI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Pearle, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <results_first_submitted>June 11, 2020</results_first_submitted>
  <results_first_submitted_qc>June 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2020</results_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stent removal, pain, kidney stones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04112160/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>normal saline 0.9%
normal saline: normal saline</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac</title>
          <description>30 mg of Ketorolac
Ketorolac: IM injection of either normal saline or Ketorolac</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>normal saline 0.9%</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac</title>
          <description>30 mg of Ketorolac</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="47" upper_limit="65"/>
                    <measurement group_id="B2" value="54" lower_limit="44" upper_limit="66"/>
                    <measurement group_id="B3" value="56" lower_limit="47" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analog Pain (VAS) Pain Scale at the baseline</title>
          <description>Scale from 0 (no pain) to 10 (worst pain of one's life), describe how much pain is experienced prior to any intervetion.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B2" value="2" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B3" value="2" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unscheduled Return to Clinic or Emergency Room</title>
        <description>Any unscheduled in-person clinical encounter secondary to renal colic following ureteral stent removal.</description>
        <time_frame>Seven days following ureteral stent removal.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>normal saline 0.9%</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30 mg of Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unscheduled Return to Clinic or Emergency Room</title>
          <description>Any unscheduled in-person clinical encounter secondary to renal colic following ureteral stent removal.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Visual Analog Pain (VAS) Pain Scale Experienced by Participant 24 Hours Following Stent Removal</title>
        <description>Perceived pain on a scale of 0-10 (0= no pain, 10= worst pain ever experienced) recorded by phone call 24 hours after stent removal.</description>
        <time_frame>Twenty-four hours following ureteral stent removal.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>normal saline 0.9%</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30 mg of Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Median Visual Analog Pain (VAS) Pain Scale Experienced by Participant 24 Hours Following Stent Removal</title>
          <description>Perceived pain on a scale of 0-10 (0= no pain, 10= worst pain ever experienced) recorded by phone call 24 hours after stent removal.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experienced an Injection Complication</title>
        <description>Determine if there is any infection site pain or reaction. Determine any complications related to administration of the medication.</description>
        <time_frame>Within thirty days post injection.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>normal saline 0.9%</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30 mg of Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced an Injection Complication</title>
          <description>Determine if there is any infection site pain or reaction. Determine any complications related to administration of the medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Pain (VAS) Pain Scale 7 Days Following Stent Removal.</title>
        <description>Perceived pain on a scale of 0-10 (0= no pain, 10= worst pain ever experienced) recorded by phone call 7 days after stent removal.</description>
        <time_frame>Seven days following ureteral stent removal.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>normal saline 0.9%</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30 mg of Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Pain (VAS) Pain Scale 7 Days Following Stent Removal.</title>
          <description>Perceived pain on a scale of 0-10 (0= no pain, 10= worst pain ever experienced) recorded by phone call 7 days after stent removal.</description>
          <units>score on a scale (0-10, 0= no pain)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Required Opioid Medication Following Ureteral Stent Removal</title>
        <description>Determine the use of opioid medications in morphine equivalents in the 24 hours following stent removal.</description>
        <time_frame>Twenty-four hours following stent removal.</time_frame>
        <population>Number of patients that had any opioid use at 24 hours post stent removal.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>normal saline 0.9%</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30 mg of Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Required Opioid Medication Following Ureteral Stent Removal</title>
          <description>Determine the use of opioid medications in morphine equivalents in the 24 hours following stent removal.</description>
          <population>Number of patients that had any opioid use at 24 hours post stent removal.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Days the Participant Missed Work</title>
        <description>Determine amount of missed work or school due to renal colic following ureteral stent removal.</description>
        <time_frame>Seven days following stent removal.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>normal saline 0.9%</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>30 mg of Ketorolac</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Days the Participant Missed Work</title>
          <description>Determine amount of missed work or school due to renal colic following ureteral stent removal.</description>
          <units>days of missed work</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.7"/>
                    <measurement group_id="O2" value="2.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>normal saline 0.9%</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac</title>
          <description>30 mg of Ketorolac</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There are inherent variations in the size/location of nephrolithiasis, surgical/stent parameters, and patient characteristics that cannot be be defined or controlled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brett Johnson</name_or_title>
      <organization>UT Southwestern Dept of Urology</organization>
      <phone>214-645-3526</phone>
      <email>brett.johnson@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

